Quarterly ResultAug 5, 2026, 07:08 AM
Eli Lilly Q2 Revenue $23.0B, +48%; Raises FY Guidance
AI Summary
Eli Lilly reported strong second-quarter 2026 financial results, with revenue increasing 48% to $23.0 billion and non-GAAP EPS rising 33% to $8.38. The company raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion, reflecting continued strong performance. Key growth drivers included Mounjaro and Zepbound, alongside significant pipeline progress for retatrutide and strategic business development activities, including multiple acquisitions and manufacturing expansion.
Key Highlights
- Q2 2026 Revenue increased 48% to $23.0 billion, driven by Mounjaro and Zepbound.
- Q2 2026 Reported EPS increased 26% to $7.94; Non-GAAP EPS increased 33% to $8.38.
- Full-year 2026 revenue guidance raised to $85.0 billion to $87.0 billion.
- Full-year 2026 non-GAAP EPS guidance updated to $35.50 to $36.50, reflecting underlying growth offset by $3.03 IPR&D charges.
- Mounjaro revenue grew 91% to $9.9 billion; Zepbound revenue grew 46% to $4.9 billion.
- Completed acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics.
- Positive Phase 3 data for retatrutide in obesity, with BLA submission planned for Q1 2027.
- Committed an additional $4.5 billion to expand Indiana manufacturing sites.
Price Impact
More from LLY